Lytix Biopharma AS (OSL:LYTIX)

G1 Therapeutics Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	577	401	195	311	533	-
Market Cap Growth	40.76%	106.12%	-37.37%	-41.63%	-	-
Enterprise Value	462	361	116	139	323	-
Last Close Price	8.46	5.88	4.86	7.76	13.75	-
PS Ratio	949.83	36.05	48.79	28.19	27.59	-
PB Ratio	6.07	3.72	3.80	2.30	2.81	-
P/TBV Ratio	6.07	3.72	3.80	2.30	2.81	-
EV/Sales Ratio	-	32.39	29.06	12.63	16.76	-
Debt / Equity Ratio	0.03	0.02	0.01	0.01	0.01	-
Asset Turnover	0.01	0.11	0.04	0.06	0.16	0.16
Quick Ratio	3.86	3.90	5.01	8.51	14.29	2.52
Current Ratio	3.86	3.91	5.06	8.55	14.33	2.56
Return on Equity (ROE)	-138.05%	-118.41%	-94.33%	-34.54%	-45.90%	-251.50%
Return on Assets (ROA)	-64.60%	-56.97%	-55.72%	-22.90%	-25.23%	-105.82%
Return on Capital (ROIC)	-85.80%	-73.84%	-64.29%	-25.01%	-28.34%	-158.25%
Earnings Yield	-15.41%	-23.48%	-45.14%	-18.03%	-9.03%	-
FCF Yield	-	-17.53%	-49.31%	-16.98%	-8.37%	-
Buyback Yield / Dilution	-	-35.05%	-1.01%	-19.50%	-26.57%	-14.56%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.